Collegium to Showcase Real-World Data on ADHD Drug at APSARD 2026
Event summary
- Collegium Pharmaceutical will present four real-world data posters on its ADHD drug Jornay PM at the APSARD 2026 Annual Conference.
- Poster sessions will cover optimal dosing, risk-benefit comparisons with Concerta, and impacts on morning/evening functioning and mental health.
- The conference runs from January 15-18, 2026, in San Diego, California.
- Jornay PM is a CNS stimulant indicated for ADHD in patients aged 6 and older.
The big picture
Collegium's focus on real-world evidence aligns with broader industry trends toward value-based healthcare, where outcomes data drives clinical decision-making. The ADHD market is highly competitive, with stimulant medications like Concerta dominating. Collegium aims to differentiate Jornay PM through its delayed-release extended-release delivery platform, targeting patients who struggle with morning dosing. The strategic emphasis on real-world data could enhance its market positioning if the results demonstrate superior efficacy or safety profiles.
What we're watching
- Competitive Positioning
- How the real-world data will position Jornay PM against established competitors like Concerta in the ADHD treatment market.
- Regulatory Dynamics
- Whether the data will influence regulatory decisions or labeling changes for Jornay PM.
- Market Adoption
- The pace at which clinicians and patients adopt Jornay PM based on the presented real-world evidence.
Related topics